Time filter

Source Type

Wrobel M.,Oddzial Kliniczny Chorob Wewnetrznych | Szymborska-Kajanek A.,Oddzial Kliniczny Chorob Wewnetrznych | Rokicka D.,Oddzial Kliniczny Chorob Wewnetrznych | Girek-Baczewska M.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | And 2 more authors.
Diabetologia Kliniczna | Year: 2014

Incretin therapy has been used in line with current guidance in treatment of type 2 diabetes for a few years. The efficacy of incretin mimetics and incretin enhancers has been proved in many clinical studies so far. Since this therapy is available on market there are concerns regarding its safety. This article is an review of current data about safety of DPP-4 inhibitors in special groups of patients: elderly, prone to hypoglycemia, or with deterioration of kidney function. It concerns also on issues associated with cardiovascular risk, pancreatitis and pancreatic cancer.

Czerwinski W.,III Oddzial Kardiologii Inwazyjnej | Debinski M.,III Oddzial Kardiologii Inwazyjnej | Szpak-Ulczok S.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | Szafert-Gesikowska E.,III Oddzial Kardiologii Inwazyjnej | And 4 more authors.
Kardiologia Polska | Year: 2013

Severe heart failure can be a rare symptom of hypocalcemia. We report a case of a 58 year-old male admitted with a diagnosis of acute coronary syndrome. The ECG showed prolonged QTc interval with severly impared left ventricular ejection fraction recognised in echocardiography. During the hospitalisation hypocalcemia due to primary hypoparathyreoidism was revealed to be the cause of those symptoms. © Polskie Towarzystwo Kardiologiczne.

Fijolek-Warszewska A.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | Nowecki Z.I.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | Lapinska G.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | Bryszewska M.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej | Kozlowicz-Gudzinska I.,Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej
Nowotwory | Year: 2013

Colorectal cancer is one of the most common cancers worldwide, including Poland. PET/CT is a relatively new diagnostic imaging method which has gained wide acceptance in oncology. The combination of anatomical imaging (CT) and metabolic imaging (PET) enables early identifi cation of proliferative changes and thus an accurate staging of cancer. In the diagnosis of recurrent colorectal cancer, PET/CT with fl uorodeoxyglucose (18F-FDG) has proven to be of high clinical value. The information obtained in this study has a signifi cant impact on patient management. When there is suspicion of relapse, it is important to use an eff ective restaging tool to accurately defi ne the extent of the recurrence and to plan the proper therapy. In the standard protocol for the 18F-FDG PET/CT study, fused images of low dose CT (without intravenous contrast agent) and PET are performed. This approach does not provide suffi cient information of local tumor or invasion to adjacent organs and vessels to enable assessment of the suitability for resectability. This information is, however, available from computed tomography when intravenous contrast agent is used. Implementation of the PET/CT protocol consisting of low dose CT, with PET followed by CT with intravenous contrast agent in the corresponding region, provides in a single study all the necessary information required to qualify patients for surgery. It may in the future become the modality of choice in the diagnosis of colorectal cancer recurrence. © Polskie Towarzystwo Onkologiczne.

Discover hidden collaborations